ES2196004T3 - Procedimiento para preparar 1,3-oxatiolanos sustituidos con propiedades antivirales. - Google Patents

Procedimiento para preparar 1,3-oxatiolanos sustituidos con propiedades antivirales.

Info

Publication number
ES2196004T3
ES2196004T3 ES93900063T ES93900063T ES2196004T3 ES 2196004 T3 ES2196004 T3 ES 2196004T3 ES 93900063 T ES93900063 T ES 93900063T ES 93900063 T ES93900063 T ES 93900063T ES 2196004 T3 ES2196004 T3 ES 2196004T3
Authority
ES
Spain
Prior art keywords
oxatiolans
prepare
substituted
procedure
antiviral properties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93900063T
Other languages
English (en)
Inventor
Tarek Mansour
Allan H L Tse
Colleen A Evans
Haolun Jin
Boulos Zacharie
Nghe Nguyen-Ba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Canada Inc
Original Assignee
IAF BioChem International Inc
Biochem Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/308,101 external-priority patent/US5047407A/en
Application filed by IAF BioChem International Inc, Biochem Pharma Inc filed Critical IAF BioChem International Inc
Application granted granted Critical
Publication of ES2196004T3 publication Critical patent/ES2196004T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE PRESENTAN PROCESOS PARA PREPARAR COMPUESTOS DE FORMULA (I) Y SUS ESTERES O SALES FARMACEUTICAMENTE ACEPTABLES, DONDE R2 ES UNA BASE PURINA O PIRIMIDINA O UN ANALOGO O DERIVADO DE ESTAS; Y Z ES S, S=O O SO2. LA INVENCION TAMBIEN SE REFIERE A INTERMEDIOS DE USO EN LA PREPARACION DE ESTOS COMPUESTOS.
ES93900063T 1989-02-08 1992-12-21 Procedimiento para preparar 1,3-oxatiolanos sustituidos con propiedades antivirales. Expired - Lifetime ES2196004T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/308,101 US5047407A (en) 1989-02-08 1989-02-08 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US56416090A 1990-08-07 1990-08-07
CA002152269A CA2152269C (en) 1989-02-08 1992-12-21 Process for preparing substituted 1,3-oxathiolanes with antiviral properties
PCT/CA1992/000557 WO1994014802A1 (en) 1989-02-08 1992-12-21 Process for preparing substituted 1,3-oxathiolanes with antiviral properties

Publications (1)

Publication Number Publication Date
ES2196004T3 true ES2196004T3 (es) 2003-12-16

Family

ID=27170036

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93900063T Expired - Lifetime ES2196004T3 (es) 1989-02-08 1992-12-21 Procedimiento para preparar 1,3-oxatiolanos sustituidos con propiedades antivirales.

Country Status (11)

Country Link
EP (1) EP0674634B1 (es)
JP (1) JP3160291B2 (es)
AT (1) ATE237613T1 (es)
AU (1) AU3154993A (es)
CA (1) CA2152269C (es)
DE (1) DE69233014T2 (es)
DK (1) DK0674634T3 (es)
ES (1) ES2196004T3 (es)
HU (1) HU226137B1 (es)
PT (1) PT674634E (es)
WO (1) WO1994014802A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6175008B1 (en) * 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
AU7954694A (en) * 1993-09-10 1995-03-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis b virus activity
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
ES2276404T3 (es) 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
IT1290447B1 (it) * 1997-03-28 1998-12-03 Zambon Spa Derivati 1,3-ossatiolanici ad attivita' antivirale
CA2285577A1 (en) 1997-04-07 1998-10-15 Triangle Pharmaceuticals, Inc. Compositions containing mkc-442 in combination with other antiviral agents
IL143867A0 (en) 1998-12-23 2002-04-21 Shire Biochem Inc Antiviral nucleoside analogues
WO2003051298A2 (en) * 2001-12-14 2003-06-26 Pharmasset Ltd. Preparation of intermediates useful in the synthesis of antiviral nucleosides
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
SI2225232T1 (sl) 2007-11-29 2012-12-31 Ranbaxy Laboratories Limited Postopek za pripravo substituiranih 1,3-oksatiolanov
US8648085B2 (en) 2007-11-30 2014-02-11 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CN102143965A (zh) 2008-09-08 2011-08-03 贝林格尔.英格海姆国际有限公司 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
UY32531A (es) 2009-03-31 2010-10-29 Boehringer Ingelheim Int Nuevos compuestos para el tratamiento de trastornos del snc
BR112013003097B1 (pt) 2010-08-12 2021-03-16 Boehringer Ingelheim International Gmbh 6-cicloalquil-pirazolopirimidinonas e composição farmacêutica
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
CN104059057A (zh) * 2014-01-03 2014-09-24 石家庄龙泽制药有限公司 拉米夫定杂质3-tu的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
JP2960164B2 (ja) * 1990-11-13 1999-10-06 バイオケム ファーマ インコーポレイテッド 抗ウイルス特性を有する置換１，３−オキサチオラン類および置換１，３−ジチオラン類
AU9125991A (en) * 1990-12-05 1992-07-08 University Of Georgia Research Foundation, Inc., The Enantiomerically pure beta -l-(-)-1,3-oxathiolane nucleosides
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
CA2105486C (en) * 1991-03-06 2003-10-28 George Robert Painter Iii Therapeutic nucleosides
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides

Also Published As

Publication number Publication date
JP3160291B2 (ja) 2001-04-25
EP0674634B1 (en) 2003-04-16
DE69233014T2 (de) 2004-01-08
ATE237613T1 (de) 2003-05-15
DE69233014D1 (de) 2003-05-22
DK0674634T3 (da) 2003-08-04
CA2152269C (en) 1999-09-21
CA2152269A1 (en) 1994-07-07
PT674634E (pt) 2003-09-30
HU9501825D0 (en) 1995-08-28
EP0674634A1 (en) 1995-10-04
HUT73655A (en) 1996-09-30
JPH08504212A (ja) 1996-05-07
AU3154993A (en) 1994-07-19
HU226137B1 (en) 2008-05-28
WO1994014802A1 (en) 1994-07-07

Similar Documents

Publication Publication Date Title
PT674634E (pt) Processos para preparar 1,3-oxatiolanos substituidos com propriedades antivirais
CA2009637A1 (en) Substituted-1,3-oxathiolanes with antiviral properties
ES2091948T3 (es) 1,3-oxatiolanos sustituidos con propiedades antiviricas.
MY105523A (en) Substituted-1,3-oxathiolanes with antiviral properties.
FI98729B (fi) Menetelmä farmaseuttisesti vaikuttavan puriinijohdannaisen valmistamiseksi
NO905300D0 (no) Pyrimidin-nukleosider og mellomprodukter.
ATE134644T1 (de) Weitere antivirale pyrimidin-nukleosiden
IL88755A (en) (1:, 2, 3:)-3-substituted-2- hydroxycyclo- butanemethanol derivatives and pharmaceutical and veterinary compositions containing the same
MY103801A (en) Dideoxydidehydrocarbocyclic nucleosides
FI891003A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten 6-substituoitujen purinyylipiperatsiinijohdannaisten valmistamiseksi
FI891004A7 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 4-substituoitujen pyratsolo/3,4-d/pyrimidiinijohdannaisten valmistamiseksi
FI900145L (fi) Menetelmä farmaseuttisesti käyttökelpoisten 1,1-diokso-kefem-4-karbotiolihappojohdannaisten valmistamiseksi
FI864970A0 (fi) Nya kristallina salter av aryloxi-propanolaminer, foerfarande foer deras framstaellning och deras anvaendning.
MY127470A (en) Process for the synthesis of chloropurine intermediates
HUT54153A (en) Process for producing purinyl- and pyrimidinyltetrahydrofuran derivatives and pharmaceutical compositions comprising same
FI910159A7 (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten 9a-hydroksi-3-okso- 4,24(25)-stigmastadieeni-26-happojohdannaisten valmistamiseksi
FI93216C (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 1,3-dioksaanialkeenihappojohdannaisten valmistamiseksi
FI910816L (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 3H-6H-1,4,5a,8a,-tetra-atsa-asenaftyleeni-3,5(4H)-dionijohdannaisten valmistamiseksi
FI922268L (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten N-difenyylialkyylialkoksisubstituoitujen 3-piperidiinikarboksyylihappojohdannaisten valmistamiseksi
ES2096559T3 (es) Interferon gamma humano, procedimiento para la preparacion de dicho interferon gamma humano, y su uso.